Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam
Viruses · 2023
DOI: 10.3390/v15091782 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Joshua S Brunton und 5 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Rubella, Measles, Mumps. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Congenital rubella syndrome is a constellation of birth defects that can have devastating consequences, impacting approximately 100,000 births worldwide each year. The incidence is much lower in countries that routinely vaccinate their population. In the US, postnatal immunization of susceptible women is an important epidemiological strategy for the prevention of rubella as the Center for Disease Control (CDC) does not recommend administering this vaccine during pregnancy due to its nature as a live attenuated virus vaccine. However, concerns that the co-administration of rubella vaccine with other immunoglobins (i.e., Rhogam) could compromise vaccine efficacy has produced warnings that can delay the administration of rubella vaccination postpartum, leaving women susceptible to the disease in subsequent pregnancies. We aimed to address whether the co-administration of the measles, mumps, and rubella (MMR) vaccine and Rhogam decreased antibody responses compared to those receiving only MMR vaccination. This retrospective cohort study utilized clinical data from 78 subjects who received the MMR vaccine and Rhogam after delivery and 45 subjects who received the MMR vaccine alone. Maternal demographics, pregnancy complications and rubella status at the start of a subsequent pregnancy were recorded for analysis. Overall, the two cohorts had similar baseline characteristics; however, lower parity was noted in the participants that received both MMR vaccination and Rhogam. Making assessments based on maternal antibody IgG index for rubella during the next pregnancy, we observed that 88% of the Rhogam + MMR vaccine group had positive serology scores, which was not significantly different from the 80% rate in the MMR-vaccine-only cohort (p = 0.2). In conclusion, no differences were observed in rubella immunity status in subsequent pregnancies in those mothers given both the MMR vaccine and Rhogam concurrently. Given these findings, warnings against co-administration of vaccines in combination with Rhogam appear unwarranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obstetrics Division, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
- Division of Quantitative Health Sciences, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
- Division of Research, Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
ORCID-Profile: Joshua S Brunton, Regan N Theiler, Elizabeth Ann L Enninga
Förderung
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Brunton, J. S., Theiler, R. N., Mehta, R., Branda, M. E., Enninga, E. A. L., & Torbenson, V. E. (2023). Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam. Viruses. https://doi.org/10.3390/v15091782
Vancouver
Brunton JS, Theiler RN, Mehta R, Branda ME, Enninga EAL, Torbenson VE. Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam. Viruses. 2023. doi:10.3390/v15091782
BibTeX
@article{Brunton2023,
author = {Brunton, Joshua S and Theiler, Regan N and Mehta, Ramila and Branda, Megan E and Enninga, Elizabeth Ann L and Torbenson, Vanessa E},
title = {Efficacy of Rubella Vaccination after Co-Inoculation with Rhogam},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15091782}
}
EUVIMED